Poor
Partially Aligned
Patient Risk:
Low
Summary
Only two of the nine claims are clearly supported by the provided label indications; the remaining sales/patent/competition claims are not supported by the supplied FDA label text, and no dosage/safety/administration claims were evaluated.
Category Scores
Accurate Statements
Rexulti is a medication for treating schizophrenia.
Supported by Indications (1): “Treatment of schizophrenia in adults and pediatric patients ages 13 years and older.”
Rexulti is a medication for treating major depressive disorder.
Supported by Indications (1): “Adjunctive treatment to antidepressants for major depressive disorder (MDD) in adults.”
Unsupported Statements
Rexulti generated $1.4 billion in net sales in 2023.
Not addressed in the provided labeling sections; no sales figures are included in the supplied label text.
Rexulti generated $1.2 billion in net sales in 2022.
Not addressed in the provided labeling sections; no sales figures are included in the supplied label text.
Rexulti achieved net sales of $1.1 billion in the United States in 2023.
Not addressed in the provided labeling sections; no sales figures are included in the supplied label text.
Rexulti contributed $313 million in net sales from international markets in 2023.
Not addressed in the provided labeling sections; no sales figures are included in the supplied label text.
Patent exclusivity for Rexulti is anticipated to expire around 2037.
Not addressed in the provided labeling sections; patent/exclusivity timing is not included in the supplied label text.
Rexulti faces competition from Abilify (aripiprazole).
Not addressed in the provided labeling sections; no competitor statements are included in the supplied label text.
Rexulti faces competition from Latuda (lurasidone).
Not addressed in the provided labeling sections; no competitor statements are included in the supplied label text.
Rexulti faces competition from Vraylar (cariprazine).
Not addressed in the provided labeling sections; no competitor statements are included in the supplied label text.
Contradictions
Important Omissions
For the MDD claim, the label specifies “adjunctive treatment to antidepressants” (not Rexulti monotherapy). The AI claim states only that it treats major depressive disorder, without the adjunctive qualifier.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims are limited to indication-level statements and non-label business/market assertions; no dosage, contraindication, warning, or monitoring instructions were provided or evaluated.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Partially Aligned
Primary Issue
Most claims (sales, patent timing, competitor framing) are not supported by the provided FDA label excerpts; the MDD indication is missing the required “adjunctive to antidepressants” qualifier.
Suggested Improvement
Limit medical indication statements to label language (e.g., specify adjunctive treatment to antidepressants for MDD) and exclude non-label items such as sales, patent-exclusivity timing, and competitive comparisons unless supported by the provided prescribing information.